Month: July 2024

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a second amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and together with the Company and Aditxt, the “Parties”) to amend the previously announced arrangement agreement dated April 1, 2024 among the Parties (as amended on July 1, 2024, the “Arrangement Agreement”), pursuant to which Aditxt, through its wholly-owned subsidiary, Adivir, will acquire all of the issued and outstanding Class A...

MIDDLEFIELD, OHIO, July 18, 2024 (GLOBE NEWSWIRE) — Middlefield Banc Corp. (NASDAQ: MBCN) today reported financial results for the six months ended June 30, 2024. 2024 Six-Month Financial Highlights (on a year-over-year basis):Net income was $8.3 million, compared to $10.0 million Pre-tax, pre-provision net income(1) was $9.7 million, compared to $13.3 million   Earnings were $1.03 per diluted share, compared to $1.23 per diluted share Net interest income after the provision for credit losses was $30.1 million, compared to $32.5 million Noninterest income increased 8.7% to $3.6 million, compared to $3.3 million Total loans increased 6.3% to a record  $1.50 billion, compared to $1.41 billion Total deposits increased 2.6% to a record $1.47 billion, compared to $1.43 billion Return on average assets annualized was 0.91%, compared...

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG) (NYSE: CGAU) has published its 2023 Environmental, Social and Governance (“ESG”) Report, which outlines the Company’s performance on sustainability-related material topics. Key highlights and achievements from the report are included below. The full report can be accessed on Centerra’s website at www.centerragold.com/sustainability. Paul Tomory, President and Chief Executive Officer of Centerra, commented “2023 was a year of meaningful progress in our sustainability journey, marked by significant achievements across the organization. We recognize that ESG contributes to the long-term sustainability, profitability and growth of our Company. Centerra’s dedication to ESG is an important aspect of our corporate identity,...

MINNEAPOLIS, July 18, 2024 (GLOBE NEWSWIRE) — Clearfield, Inc. (NASDAQ: CLFD), the leader in community broadband fiber connectivity, today announced that its third quarter ended June 30, 2024, results will be released on Thursday, August 1, 2024, after the close of the market. The company will host a conference call at 5:00 p.m. Eastern time (4:00 p.m. Central time) to discuss its financial results with the investment community. Financial results will be available on the Investor Relations section of the company’s website along with an earnings presentation to accompany management’s prepared remarks. Date: Thursday, August 1, 2024Time: 5:00 p.m. Eastern time (4:00 p.m. Central time)U.S. dial-in: 1-877-407-0792International dial-in: 1-201-689-8263 The conference call will be webcast live and available for replay here. An audio replay...

HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Formulation. Dr. Tenjarla brings over 20 years of extensive experience in drug development to Serina. Dr. Tenjarla joins Serina Therapeutics from Takeda Pharmaceuticals, where he served as Vice President and Head of Drug Product Development and Process Chemistry Development/Outsourcing in Pharmaceutical Sciences. In this role, he provided technical and strategic leadership to global teams, overseeing phase-appropriate development from Phase 1 through product validation and PAI...

PARSIPPANY, N.J., July 18, 2024 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal third quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, Aug 9, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on Aug 9, 2024, via the embecta investor relations website and archived on the website for one year. About embecta embecta is a global diabetes care company that is leveraging its 100-year...

PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor...

2nd Quarter 2024 Highlights:Net income was $44.7 million for the current quarter, an increase of $12.1 million, or 37 percent, from the prior quarter net income of $32.6 million and a decrease of $10.2 million, or 19 percent, from the prior year second quarter net income of $55.0 million. The net interest margin as a percentage of earning assets, on a tax-equivalent basis, for the current quarter was 2.68 percent, an increase of 9 basis points from the prior quarter net interest margin of 2.59 percent. The loan portfolio of $16.852 billion increased $119 million, or 3 percent annualized, during the current quarter. The loan yield of 5.58 percent in the current quarter increased 12 basis points from the prior quarter loan yield of 5.46 percent and increased 46 basis points from the prior year second quarter loan yield of 5.12 percent. Non-interest...